相关实验视频

Updated: Jun 13, 2025

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

用突变对抗突变:进化地调整DNA适应器,用于高亲和度识别SARS-CoV-2突变尖端蛋白

Qing Wang¹, Jiuxing Li¹, Zijie Zhang¹

¹Department of Biochemistry and Biomedical Sciences, McMaster University, 1280 Main Street West, Hamilton, Ontario, L8S 4K1, Canada.

Angewandte Chemie (International ed. in English)

|September 11, 2024

概括

科学家们开发了一个DNA吸收器来检测COVID-19的Omicron变种. 修改后的阿巴,MBA5SA1,显示了超过100倍的结合亲和力,并使患者唾液中的敏感变体检测成为可能.

科学领域:

分子生物学分子生物学
病毒学病毒学
生物技术是生物技术.

背景情况:

SARS-CoV-2 变种的快速出现对准确的诊断构成了重大挑战.
现有的诊断工具很难跟上病毒突变的步伐,需要新的检测策略.

研究的目的:

开发一种能够识别和结合SARS-CoV-2 Omicron变异的进化DNA吸收体.
提高诊断能力,快速识别新的病毒株.

主要方法:

一个最初被选择用于野生型SARS-CoV-2尖端蛋白的DNA吸管体的体外进化.
深度测序,以分析在选择压力下的aptamer变体竞争.
开发和实施一种与酶相关的阿巴酶结合试验 (ELABA) 用于变种检测.

主要成果:

一种新型的阿普坦,MBA5SA1,产生了22个突变,对Omicron亚变种尖端蛋白 (从纳米到皮科莫尔) 具有100倍以上的结合亲和力.
在严格的实验室选择下,MBA5SA1与其父胺体相比表现出优越的结合.
使用MBA5SA1的ELABA试验在检测患者唾液样本中的Omicron变体中获得了86.5%的灵敏度和100%的特异性.

结论:

通过调整它们的识别元素,工程化aptamer可以有效地对抗病毒突变.
进化的阿普坦MBA5SA1为敏感和特定检测SARS-CoV-2 Omicron变种提供了一个有前途的工具.
这种方法有可能快速开发针对未来流行病威胁的诊断方法.

关键词:

亚普特美尔 (Aptamer) 是一种药物.在 COVID-19 疫情中,诊断诊断诊断诊断分子识别分子识别这就是SARS-CoV-2病毒.

更多相关视频

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

High-throughput Confocal Imaging of Quantum Dot-Conjugated SARS-CoV-2 Spike Trimers to Track Binding and Endocytosis in HEK293T Cells

High-throughput Confocal Imaging of Quantum Dot-Conjugated SARS-CoV-2 Spike Trimers to Track Binding and Endocytosis in HEK293T Cells

Published on: April 21, 2022

相关概念视频

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...